The latest price target for Cytokinetics (NASDAQ:CYTK) was reported by Barclays on April 6, 2026. The analyst firm set a price target for $95.00 expecting CYTK to rise to within 12 months (a possible 45.24% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytokinetics (NASDAQ:CYTK) was provided by Barclays, and Cytokinetics maintained their overweight rating.

The last upgrade for Cytokinetics Inc happened on December 19, 2025 when Goldman Sachs raised their price target to $95. Goldman Sachs previously had a neutral for Cytokinetics Inc.

The last downgrade for Cytokinetics Inc happened on August 13, 2024 when Goldman Sachs changed their price target from $85 to $60 for Cytokinetics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on April 6, 2026 so you should expect the next rating to be made available sometime around April 6, 2027.

While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a maintained with a price target of $87.00 to $95.00. The current price Cytokinetics (CYTK) is trading at is $65.41, which is out of the analyst’s predicted range.